Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Phendimetrazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 5/20 | 0.51 |
| ▸ | SLC6A3 known ✓ | Q01959 | 5/20 | 0.51 |
| ▸ | HTR1A | P08908 | 1/20 | 1.00 |
| ▸ | HTR2B | P41595 | 2/20 | 0.51 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.43 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.43 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | HRH1 | P35367 | 1/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phendimetrazine SCHEMBL15064942 | 1.00 | HTR1A (1.00) | HTR1ASLC6A2SLC6A3HTR2BADRA1A | |
| Phendimetrazine SCHEMBL598950 | 1.00 | HTR1A (1.00) | HTR1ASLC6A2SLC6A3HTR2BADRA1A | |
| Phendimetrazine SCHEMBL49481 | 1.00 | HTR1A (1.00) | HTR1ASLC6A2SLC6A3HTR2BADRA1A | |
| Phendimetrazine SCHEMBL678276 | 0.98 | HTR1A (0.96) | HTR1ASLC6A2SLC6A3HTR2BADRA1A | |
| Phendimetrazine SCHEMBL678073 | 0.96 | HTR1A (0.93) | HTR1ASLC6A2SLC6A3HTR2BADRA1A | |
| Phendimetrazine SCHEMBL160376 | 0.87 | HTR1A (0.75) | HTR1ASLC6A2SLC6A3HTR2BADRA1A | |
| Phendimetrazine SCHEMBL160375 | 0.87 | HTR1A (0.75) | HTR1ASLC6A2SLC6A3HTR2BADRA1A | |
| Phendimetrazine SCHEMBL29554688 | 0.87 | HTR1A (0.75) | HTR1ASLC6A2SLC6A3HTR2BADRA1A | |
| Phendimetrazine SCHEMBL29353044 | 0.87 | HTR1A (0.75) | HTR1ASLC6A2SLC6A3HTR2BADRA1A | |
| Phendimetrazine SCHEMBL4381184 | 0.87 | HTR1A (0.75) | HTR1ASLC6A2SLC6A3HTR2BADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1264 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4654966-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF OBESITY AND DISEASES ASSOCIATED WITH FAT CELL ENLARGEMENT | MELLICELL, INC. (US) | 2025-12-03 | — | — | EP | claimed |
| WO-2025137653-A1 | METHODS AND COMPOSITIONS OF POLYCYCLIC AND A DUAL ACTING NITROXIDE COMPOUNDS FOR TREATMENT OF FAT CELL ASSOCIATED DISEASES | MELLICELL, INC. (US) | 2025-06-26 | — | — | WO | claimed |
| WO-2024159211-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF OBESITY AND DISEASES ASSOCIATED WITH FAT CELL ENLARGEMENT | MELLICELL, INC. (US) | 2024-08-02 | — | — | WO | claimed |
| US-20190127433-A1 | GLUCAGON/GLP-1 RECEPTOR CO-AGONISTS | UNIV INDIANA RES & TECH CORP (US) | 2019-05-02 | — | — | US | claimed |
| US-10174093-B2 | Glucagon/GLP-1 receptor co-agonists | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2019-01-08 | — | — | US | claimed |
| US-20170349642-A1 | GLUCAGON/GLP-1 RECEPTOR CO-AGONISTS | UNIV INDIANA RES & TECH CORP (US) | 2017-12-07 | — | — | US | claimed |
| US-9758562-B2 | Glucagon/GLP-1 receptor co-agonists | Indiana University and Technology Corporation (US) | 2017-09-12 | — | — | US | claimed |
| US-20160058881-A1 | PRODRUGS WITH PROLONGED ACTION | INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION | 2016-03-03 | — | — | US | claimed |
| EP-2986314-A2 | PRODRUGS WITH PROLONGED ACTION | Indiana University Research and Technology Corporation (US) | 2016-02-24 | — | — | EP | claimed |
| CN-105324125-A | Prodrugs with prolonged action | UNIV INDIANA RES & TECH CORP | 2016-02-10 | — | — | CN | claimed |
| US-20150238441-A1 | Modulation of Branched Amino Acid Concentrations to Treat Metabolic Diseases | UNIVERSITY OF ROCHESTER (US) | 2015-08-27 | — | — | US | claimed |
| WO-2014152460-A2 | PRODRUGS WITH PROLONGED ACTION | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2014-09-25 | — | — | WO | claimed |
| WO-2014055977-A2 | MODULATION OF BRANCHED AMINO ACID CONCENTRATIONS TO TREAT METABOLIC DISEASES | UNIVERSITY OF ROCHESTER (US) | 2014-04-10 | — | — | WO | claimed |
| EP-2487184-A1 | Glucagon/GLP-1 receptor co-agonists | Indiana University Research and Technology Corporation (US) | 2012-08-15 | — | — | EP | claimed |
| WO-2011116139-A2 | IMPROVED PHARMACEUTICAL COMPOSITIONS AND METHODS OF DELIVERY | CHIASMA INC. (US) | 2011-09-22 | — | — | WO | claimed |
| WO-2009049105-A2 | METHODS FOR INDUCING SATIATION | GELESIS, INC. (US) | 2009-04-16 | — | — | WO | claimed |
| US-20260131089-A1 | DRUG DELIVERY DEVICES AND METHODS FOR ADMINISTERING SUBSTANCES TO A BODY CAVITY BY HETEROGENOUS AEROSOLIZATION FOR TREATMENT OF BINGE-EATING DISORDERS AND/OR OBESITY | APTARGROUP, INC. (US) | 2026-05-14 | — | — | US | disclosed |
| US-20260103499-A1 | BIOREVERSABLE PROMOIETIES FOR NITROGEN-CONTAINING AND HYDROXYL-CONTAINING DRUGS | HAN JIE (US) | 2026-04-16 | — | — | US | disclosed |
| US-5527788-A | Method and composition for treating obesity comprising dehydroepiandrosterone (DHEA), or a derivative thereof, and an anorectic agent | LOUISIANA STATE UNIV. MEDICAL CENTER FOUNDATION (US) | 1996-06-18 | — | — | US | disclosed |
| EP-0647448-A1 | Orally administrable opioid formulations having extended duration of effect | Euroceltique S.A. (LU) | 1995-04-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160058881-A1 | PRODRUGS WITH PROLONGED ACTION | VIP, GIPR, VIPR2 | SLC6A2 598/4885SLC6A3 1040/4885HTR1A 282/4885 |
| US-20260131089-A1 | DRUG DELIVERY DEVICES AND METHODS FOR ADMINISTERING SUBSTANCES TO A BODY CAVITY BY HETEROGENOUS AEROSOLIZATION FOR TREATMENT OF BINGE-EATING DISORDERS AND/OR OBESITY | CACNG6, MC5R, CRH | SLC6A2 782/4885SLC6A3 384/4885HTR1A 114/4885 |
| US-20170349642-A1 | GLUCAGON/GLP-1 RECEPTOR CO-AGONISTS | GLP1R, GCGR, GIPR | SLC6A2 2392/4885SLC6A3 1722/4885HTR1A 230/4885 |
| US-20190127433-A1 | GLUCAGON/GLP-1 RECEPTOR CO-AGONISTS | GLP1R, GCGR, GIPR | SLC6A2 2392/4885SLC6A3 1722/4885HTR1A 230/4885 |
| US-20260103499-A1 | BIOREVERSABLE PROMOIETIES FOR NITROGEN-CONTAINING AND HYDROXYL-CONTAINING DRUGS | CBR1, CBR3, SIGMAR1 | SLC6A2 327/4885SLC6A3 167/4885HTR1A 1326/4885 |
| US-10174093-B2 | Glucagon/GLP-1 receptor co-agonists | GLP1R, GCGR, GIPR | SLC6A2 2392/4885SLC6A3 1722/4885HTR1A 230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.